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ABSTRACT 
RNA interference plays a significant role in manipulating cellular and viral mechanisms to maintain latency 
during HIV-1 infection. HIV-1 produces several microRNAs including one from the TAR element which 
alter the host’s response to infection. Since cyclin/cdk complexes are important for viral transcription, these 
studies focus on the possible cdk inhibitors that inhibit viral transcription, without affecting normal cellular 
mechanisms. Roscovitine and Flavopiridol are well-studied cdk inhibitors that are effective at suppressing 
their target cdks at a low IC50. These cdk inhibitors and possibly future generations of drugs are affected by 
microRNA mechanisms. From our studies, we developed a third generation derivative called CR8#13. In 
cells that lack Dicer there was a higher level of basal viral LTR-reporter transcription. When drugs, 
specifically Flavopiridol and CR8#13 were added, the transcriptional inhibition of the LTR was less potent 
in cells that lacked Dicer. Also, after transfection with HIV-1 clone (pNL4.3), CR8 and CR8#13 derivatives 
were shown to be more effective viral transcription inhibitors in cell lines that contained Dicer (T-cells) as 
compared to Dicer deficient lines (monocytes). We next asked whether the addition of CR8 or CR8#13 could 
possibly increase levels of TAR microRNA in HIV-1 LTR containing cells. We demonstrate that the 3’TAR 
microRNA is produced in higher amounts after drug treatment, resulting in microRNA recruitment to the 
LTR. MicroRNA recruitment results in chromatin alteration, changes in Pol II phosphorylation and viral 
transcription inhibition. In conclusion, our results indicate that viral microRNA, specifically the TAR 
microRNA produced from the HIV-1 LTR is responsible for maintaining latent infections by manipulating 
host cell mechanisms to limit transcription from the viral LTR promoter. With the microRNA machinery 
present, cdk inhibitors are able to significantly increase the amount of TAR microRNA, leading to 
downregulation of viral LTR transcription. 
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INTRODUCTION 
 
Human immunodeficiency virus-1 (HIV-1) is the 
etiological agent of acquired immunodeficiency syndrome 
(AIDS).  Highly active antiretroviral therapy (HAART) is 
currently the most effective HIV-1 treatment and has been 
shown to significantly reduce AIDS-related mortality.   
Since latently infected cells still produce viral RNA and 
even small amounts of infectious virus, there is a chance 
of mutational escape from cells treated with drugs.   387 
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Current HIV-1 therapies, including HAART, are mostly 
ineffective at eliminating the virus and also are the main 
cause of drug-resistant variants. 
 
RNA interference (RNAi) is a regulatory mechanism 
conserved in higher eukaryotes, such as primates and mice.  
RNAi involves small RNA molecules that guide a protein 
effecter complex to a complementary or mostly 
complementary sequence of nucleic acid.  The end result is 
the down regulation of protein expression through either 
transcriptional silencing, cleavage of target mRNA or 
inhibition of translation (Agrawal et al, 2003; Bartel, 2004). 
Exogenously introduced dsRNA is recognized by Dicer, and 
cleaved into characteristic 21 nucleotide segments with 2 
nucleotide 3’overhangs (siRNAs and microRNAs) that 
direct the RNAi machinery for sequence-specific inhibition 
of mRNA expression. microRNAs are also produced from 
genomic DNA that is transcribed by RNA polymerase II. 
Endogenously expressed RNA can be involved in RNAi 
through a slightly different pathway involving Drosha-
mediated cleavage of RNA stem-loops in the nucleus, 
followed by export to the cytoplasm by Exportin-5, and 
finally cleavage by Dicer to generate a small RNA duplex 
approximately 22 nucleotides in length with a two 
nucleotide 3’ overhang on each strand (Hannon, 2002). One 
strand of the microRNA duplex is incorporated into 
Argonaute-containing effector complexes, which silence 
gene expression through two distinct mechanisms. In the 
first, the small RNA associates with the RNA-induced 
silencing complex (RISC) and guides the complex to a 
complementary sequence of mRNA where a member of the 
Argonaute family of proteins cleave the target mRNA, 
leading to silencing of a gene. Alternatively, the microRNA 
may guide the RISC complex to a somewhat 
complementary region in the 3’UTR of the mRNA. In 
addition to attaching the RISC complex, the RNA can 
associate with the RNA-induced initiation of transcriptional 
silencing (RITS) complex. Similar to the RISC mechanism, 
the microRNA guides this complex to a complementary 
region of chromosomal DNA and recruits factors that 
modify the chromatin structure and induce transcriptional 
silencing (Volpe et al, 2002; Matzke and Birchler, 2005). 
 
Several viruses encoding microRNAs have already been 
identified, including human cytomegalovirus, human 
herpesevirus 8, Epstein Barr virus, and herpes simplex virus 
(Grey et al, 2005; Pfeffer et al, 2005; Umbach et al, 2008). 
The functions of a number of viral microRNA have been 
dissected and they appear capable of regulating both viral 
and cellular genes (Dykxhoorn, 2007). In terms of HIV-1, 
several previous studies have reported the production of 
microRNAs from the TAR, miR-H1, nef and env RNAs 
(Omoto et al, 2004; Provost et al, 2006; Klase et al, 2007; 
Kaul et al, 2009). All or few of the HIV-1 generated 
microRNA could potentially inhibit viral replication, block 
translation of viral proteins, or cause remodeling of the viral 
genome. Thus, RNAi-based strategies have considerable 
therapeutic potential against HIV-1 infection. 
 
The majority of current therapies target viral proteins. There 
is a need for development of host gene-based therapies as 
these are most probably resistant to mutations. One attractive 
host candidate for antiviral therapeutics is the cell cycle 
machinery. The host cell cycle is dependent on the activity of 
cyclin-dependent kinases (cdks) and their catalytic cyclin 
subunits.  The cdk/cyclin complexes aid in the advancement 
of eukaryotic cell through the G1/S and G2/M cell cycle 
checkpoints.  For the G1/S checkpoint, the cdk2/cyclin E 
complex phosphorylates the retinoblastoma (Rb) protein 
(Athanassiou et al, 2004). HIV-1 has the ability to 
manipulate the cdk/cyclin mechanisms within a cell to 
support its own life cycle. For example, HIV-1 targets the 
cdk2/cyclin E complex to allow cells to pass through the 
G1/S checkpoint, enabling transcription of integral 
proliferative genes to increase HIV-1 genome replication 
(Nekhai et al, 2002). cdk/cyclin complexes are also linked to 
the viral proteins through interaction with the vital HIV-1 
Tat (transactivator of transcription) protein. Tat is the main 
transcriptional activator of the HIV-1 LTR and also induces 
some cellular genes to help maintain virus production and/or 
cell survival (Bohan et al, 1992; Zhou et al, 2000). Tat binds 
the viral TAR element, and the Tat-TAR complex recruits 
viral and cellular components to initiate and elongate the 
viral promoter. For example, Tat  recruits the pTEFb 
elongation complex to the promoter. The activated 
components of this complex, cdk9 and cyclin T1, then 
hyper-phosphorylate the large subunit of the RNA 
polymerase II C-terminal domain and other factors to 
activate transcription elongation (Kim et al, 2002). 
Therefore, cdk/cyclin inhibitors are potential HIV-1 
therapeutics. 
 
The two highly studied cdk inhibitors in relation to HIV are 
Roscovitine and Flavopiridol, which inhibit cdk1, 2, 5, 7, 9 
and cdk1, 2, 4, and 9, respectively (Haesslein and Jullian, 
2002; Vandromme et al, 2006; Oumata et al, 2008). 
Roscovitine is most effective against cdk2 and cdk9 at an 
average IC50 of <300nM and Flavopiridol inhibits cdk9 at 
an IC50 of 3nM. A lower IC50 enables these drugs to be 
more effective at suppressing the viral gene expression, 
rather than normal cellular promoters that may use either 
cdk2 or cdk9 for their transcription. More potent and specific 
analogs have been developed based on these two initial 
compounds. Cyc202 (R-roscovitine) targets the cdk2/cyclin 
E complex by binding to ATP pockets and allows apoptosis 
to occur in HIV-1 infected T-cells, monocytes, and 
peripheral blood mononuclear cells (Agbottah et al, 2005). 
Recently, we have investigated whether derivatives of 
Cyc202 could potentially inhibit viral transcription at a lower 
IC50. Treatment with Cyc202 was able to inhibit uploading 
of the cdk2/cyclin E and cdk9/cyclin T1 complexes onto 
HIV-1 DNA. A slight alteration at the purine ring of Cyc202 
resulted in a second generation drug, CR8. Here, CR8 and its 
third generation derivatives have been tested for the potency 
and specificity of inhibiting viral transcription. Results 
related to these second and third generation drugs along with 
the potential need for functional microRNA machinery will 
be discussed here. 
 
MATERIALS AND METHODS 
 
Cell culture 
TZM-bl cell lines were grown in Dulbecco’s modified 
Eagle’s medium supplemented with fetal bovine serum 
(FBS) (10%, v/v), 2mM L-glutamine, and antibiotics 
(penicillin 100U/ml, streptomycin 100mg/ml) (cDMEM). 388 
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Selectivity Name ACH2 J1.1 OM10.1 U1 CEM Jurkat U937
High CR8 (10 uM) ++++ +++ +++ ++++ + ++ ++
CR6 (10 uM) +++ +++ +++ +++ + ++ ++
Meriolin4 (10 uM) +++ +++ +++ +++ + ++ ++
Meriolin5 (10 uM) +++ ++ ++++ - - - ++
Meriolin 6 (10 uM) +++ +++ ++++ -- - - ++
M o d e r a t e M e r i o l i n  3 ( 1 0  u M ) + + +---- -
V a r i o l l i n  B ( 1 0  u M ) + + +---- -
MR3 (10 uM) ++ - + - - - -
MSL2104 (10 uM) ++ - - + - - -
MSL2106 (10 uM) ++ - + - - - -
MSL 2102 (10 uM) ++ - + - - - -
MC136 (10 uM) ++ ++ +++ ++ ++ ++ ++
Poor MSL2039 (10 uM) - - - -- - - -
1 - m e t h y l - 7 - b r o m o - i n d i r u b i n - 3 ' - o x i m e ( 1 0  u M ) ------ -
M C 1 3 5 ( 1 0  u M ) ------ -
M S L 2 1 0 9 ( 1 0  u M ) ------ -
MSL2108 (10 uM) - - - - - -
S - p e r h a r i d i n e ( 1 0  u M ) ------ -
R - D R F 0 5 3 ( 1 0  u M ) ------ -
HCT116 WT and HCT116 Dicer -/- cell lines were grown in 
McCoy’s medium supplemented with FBS (10%, v/v), 2mM 
L-glutamine, and antibiotics (penicillin 100U/ml, 
streptomycin 100mg/ml).  CEM, ACH2, Jurkat and U937 
cells were grown in RPMI 1640 supplemented with FBS, L-
glutamine, and antibiotics (penicillin 100U/ml, streptomycin 
100mg/ml). All cell lines were maintained at 37ºC in 5% 
(v/v) CO2. ACH2 cells are infected with HIV-1; TZM-bl 
cells contain a stably-integrated HIV-1 LTR-Luciferase 
reporter; CEM, Jurkat, and U937 cells are uninfected. 
Transfections were carried out using Attractene (Qiagen) 
lipid reagent. Cells were cultured to confluence and pelleted 
at 4°C for 15min at 3,000rpm. The cell pellets were washed 
twice with 25ml of phosphate-buffered saline (PBS) with 
Ca2+ and Mg2+ (Quality Biological) and centrifuged once 
more. Cell pellets were resuspended in lysis buffer (50mM 
Tris-HCl, pH 7.5, 120mM NaCl, 5mM EDTA, 0.5%, v/v, 
NP-40, 50mM NaF, 0.2mM Na3VO4, 1mM DTT, one 
complete protease cocktail tablet/50ml (Roche) and 
incubated on ice for 20min, with gentle vortexing every 
5min. Cell lysates were transferred to eppendorf tubes and 
were centrifuged at 10,000rpm for 10min. Supernatants 
were transferred to a fresh tube where protein 
concentrations were determined using Bio-Rad protein 
assay (Bio-Rad, Hercules, CA). 
 
Drug screening and cell counting 
HIV-1 infected and uninfected cells were treated with 
nineteen inhibitors (Table 1) at 10µM concentration. Among 
the inhibitors were meriolins (Bettayeb et al, 2007) and 
variolins (Simone et al, 2005), which have exhibited distinct
 
cdk inhibitory activities. Another set of drugs used were 
derived from 2,6,9-trisubstituted cdk inhibitory purines using 
a classical medicinal chemistry approach (Oumata et al, 
2008). Some of these compounds are 6-aminomethylene-
biaryl analogs of CYC202.  Among these inhibitors, CR8, an 
analog bearing a 2-pyridyl on position 4 of its phenyl ring, 
was created (Galons et al, 2010).  Table 2 includes HIV-1 
infected and uninfected cells, which were treated with 
eighteen Roscovitine/CR8 derivatives at 50nM 
concentration.  Forty-eight hours after treatment, cytotoxicity 
was primarily determined by trypan blue exclusion. Cells 
were counted to determine cell death after 48hrs. 
 
RT-PCR and primers 
For mRNA analysis of cdk9 related genes following drug 
treatments, total RNA was isolated from cells using Trizol 
(Invitrogen) according to the manufacturer’s protocol.  A 
total of 1µg of RNA from the RNA fraction was treated 
with 0.25mg/ml DNase I for 60min, followed by heat 
inactivation at 65°C for 15min.  A total of 1µg of total 
RNA was used to generate cDNA with the iScript cDNA 
Synthesis kit (Bio-Rad) using oligo-dT reverse primers. 
 
Electroporation and reverse transcriptase assay 
For electroporations, Jurkat and U937 cells were 
resuspended at 3 million cells in 250µl of RPMI.   Five 
microgram of pNL4-3 was then added to the cell 
suspension.  Cells were pulsed a single time at 210V, 800µF, 
and low resistance.  Electroporated cells were immediately 
transferred to RPMI-1640 with L-glutamine and 
Penicillin/Streptomycin with 10% (v/v) FBS and plated in 6-
well plates. Twenty four hours-post electroporation, cells 
were treated with drugs for additional 48hrs and harvested 
for RT analysis.  RT assays were performed as described in 
((Guendel et al. 2009; Easley et al. 2010). 
 
Poly-A RT-PCR 
For poly-A RT-PCR detection of microRNAs, 500ng of 
RNA from the microRNA-enriched fraction was used to 
generate cDNA using the Quantimir kit (SBI) according to 
the manufacturer’s protocol.  Briefly, small RNA species 
are poly-adenylated and then reverse transcription 
reactions are performed with a company-provided RT 
primer. For PCR, a universal reverse primer is provided by 
the manufacturer. Specific microRNA forward primers are 
identical in sequence to the microRNA of interest. PCR 
products corresponding to the amplified microRNAs were 
separated in a 3.5% (w/v) agarose gel and quantified using 
the Kodak 1D software. 
 
Table 1. Screening of various CDK inhibitors in HIV-1 cell killing assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibition:  -  +  ++  +++  ++++ 
Percentage:  1-5%  ~25%  ~50%  ~75%  ~90% 389 
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Table 2. Screening of Roscovitine/CR8 derivatives in HIV-1 cell killing assay. 
 
Selectivity  Name    ACH2  J1.1  OM10.1  U1  CEM  Jurkat  U937 
High  MRT‐033  (50 nM)  ++++  ++  +++  ++  +  ++  ++ 
  MRT3‐028  (50 nM)  +++  +++  +++  +  ++  ++  ++ 
Moderate  MRT2‐006  (50 nM)  +  ++  ++  + ‐   ++  +++ 
  BJFP1164  (50 nM)  ++  ++  ++  +  +  ++  ++ 
  MRT2‐004  (50 nM)  ++  ++  ++  +  +  ++  ++ 
  MRTI‐004  (50 nM)  ++  ++  ++  +  +  ++  ++ 
  MRT3‐007  (50 nM)  ++  ++  ++  ++  +  +  + 
  BJFP1155  (50 nM)  ++  ++  ++  +  +  +  + 
  BJFP1162  (50 nM)  ++  ++  ++  +  +  +  + 
  BJFP1167  (50 nM)  ++  ++  ++  +  +  ++  ++ 
Poor  MRT3‐024  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  BJFP1154  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  MRT2‐007  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  MRT1‐006  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  BJFP1168  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  MRT1‐008  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  MRT1‐028  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
  MRT1‐007  (50 nM)  ‐   ‐  ‐   ‐  ‐  ‐  ‐  
 
 
 
 
 
Chloramphenicol acetyltransferase (CAT) assay 
Various cells lines were transfected with the HIV-1 LTR-
CAT plasmid and pc-Tat to initiate the LTR transcription, 
and subsequently subjected to various drug treatments.   
After 48hrs, cells were lysed and CAT assays were 
perfomred as previously described (Guendel et al, 2009; 
Van Duyne et al, 2008; Easley et al, 2010). 
 
Luciferase assay 
TZM-bl cells were transfected with pc-Tat (0.5µg) using 
Attractene reagent (Qiagen) according to the 
manufacturers' instructions.  Twenty-four hours later, cells 
were treated with DMSO or the indicated compound. 
Forty-eight hours-post drug treatment, luciferase activity 
of the firefly luciferase was measured with the BrightGlo 
Luciferase Assay (Promega).  
 
RNase protection assay (RPA) 
Total RNA was extracted from TNF-treated CEM and 
ACH2 cells follow by drug treatment with Cyc202 
(500nM), CR8 (100µM), CR8#13 (50nM), and 
Flavopiridol (50nM) for 48hrs using Trizol reagent 
(Invitrogen). RNase protection assays were performed as 
previously described (Klase et al, 2007). 
 
Chromatin immunoprecipitation assay (ChIP) 
TZM-bl cells were treated with TSA for 7 days and 
processed for ChIP. For ChIP, approximately 5×10
6 cells 
were used per IP.  ChIP assays were performed as 
previously described. PCR was performed using 0.1µM of 
HIV-1 LTR primers (Klase et al, 2007; Guendel et al, 
2009; Easley et al, 2010). 
RESULTS 
 
Effect of inhibitors on HIV-1 infected and uninfected cells 
We reasoned that the specific targeting of cell cycle and 
cdk regulators with small molecule therapeutics might 
provide better insights into how to inhibit HIV-1 infected 
cells. To that end, HIV-1 infected and uninfected cells 
were studied by culturing ACH2, J1.1, OM10.1, U1 and 
uninfected CEM, Jurkat T-cells, and U937 in media with 
inhibitor concentration of 10µM to compare different 
classes of inhibitors. Cells were treated for 48hr and cell 
viability was determined using trypan blue exclusion 
method.  Results of such a screen from the 19 inhibitors 
are shown in Table 1 where percent of dead cells are 
indicated after various drug treatments. A number of drugs 
caused death in HIV-1 infected cells much more 
efficiently than uninfected cells. The inhibitors were 
classified into three categories: high, moderate or poor, 
according to their effect on cellular viability in both HIV-1 
infected and uninfected cells. The top candidate that killed 
HIV-1 infected cells, while having little cell death in 
uninfected cells was CR8, a second generation drug 
derived from Cyc202. 
 
In an attempt to test a third generation of drugs, we made 18 
new derivatives of the CR8 with slight modifications for 
testing against HIV-1.  Similar to the previously performed 
assay for cdk inhibitors, infected ACH2, J1.1, OM10.1, U1 
and uninfected CEM, Jurkat T-cells, and U937 were 
cultured in media with low inhibitor concentration (50nM) 
to evaluate relative efficacies of the CR8 derivatives. Cells 
were treated for 48hrs and cell viability was determined 
Inhibition:  -  +  ++  +++  ++++ 
Percentage:  1-5%  ~25%  ~50%  ~75%  ~90% 390 
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using trypan blue exclusion method.  Results of such a 
screen from the 18 CR8 derivatives are shown in Table 2 
where percent of dead cells are indicated after various drug 
treatments. Interestingly, the two derivatives that caused 
maximum death in infected cells were minimally toxic to 
uninfected control cells.   
 
This prompted us to determine if derivatives exhibiting 
minimal cell killing of infected cells were able to inhibit 
viral transcription. TZM-bl cells that have an integrated 
HIV-1 LTR-luciferase reporter were transfected with pc-Tat 
(encodes HIV-1 Tat protein) and then treated with 18 CR8 
derivatives. The addition of Tat enables activated 
transcription of HIV-1 promoter driving luciferase in these 
cells. Treated cells were assayed 48hrs after Tat transfection 
and drug treatment. Among the tested inhibitors indicated in 
Table 2, luciferase assays revealed 9 analogs as efficiently 
decreasing viral transcription of the fully chromatinized 
HIV-1 promoter (Figure 1A).  The compound BJFP1154 
(CR8#13), exhibited the greatest transcriptional inhibition 
of the HIV-1 LTR, although it did not affect cell viability as 
shown in Table 2. 
 
To further validate the cell death results for a few of the 
compounds, more quantitative MTT assay were performed 
(Figures 1B).  CR8, MRT-033, and BJFP1154 (CR8#13) 
were tested on all infected ACH2, J1.1, OM10.1, U1 and 
uninfected CEM, Jurkat T-cells, and U937 cells.  They were 
cultured in media with both low (50nM) and high (10µM) 
inhibitor. CR8 exhibited significant cell killing of infected 
cells over uninfected cells at both high and low 
concentrations. MRT-033 exhibited killing of infected cells, 
ACH2, U1 and OM10.1 cells.  However, both compounds, 
CR8 and MRT-033 still exhibited some cell killing of 
uninfected cells. CR8#13 showed minimal cell killing even 
at the high concentration. 
 
Data in Figure 1 show that there are a number of inhibitors 
that effectively decrease HIV-1 transcription and have no 
effect on cell viability or toxicity.  For instance drugs, such 
as MRT3-028 exhibited significant cell killing in infected 
cells and were also proficient in HIV-1 transcription 
inhibition (Figure 1A, Lane 12).  Similarly, BJFP1155 and 
BJFP1164 are capable of moderate cell killing of infected 
cells, while also having the ability to block HIV-1 
transcription (Figure 1A, Lanes 16 and 18).  BJFP1154 
(CR8#13) was unique in that it displayed very little 
cytotoxicity, while causing the most significant decrease of 
HIV-1 transcription.  This makes CR8#13 a novel new drug 
candidate to control HIV-1 transcription and infection. 
 
A: 
10000
20000
30000
40000
50000
60000
R
a
w
 
L
u
c
i
f
e
r
a
s
e
U
n
i
t
s
0
D
M
S
O
C
R
8
M
R
T
2
-
0
0
6
M
R
T
2
-
0
0
4
M
R
T
2
-
0
0
7
M
R
T
1
-
0
0
8
M
R
T
1
-
0
2
8
M
R
T
1
-
0
0
6
M
R
T
1
-
0
0
7
M
R
T
1
-
0
0
4
M
R
T
3
-
0
2
4
M
R
T
3
-
0
2
8
M
R
T
-
0
3
3
M
R
T
3
-
0
0
7
B
J
F
P
1
1
5
4
B
J
F
P
1
1
5
5
B
J
F
P
1
1
6
2
B
J
F
P
1
1
6
4
B
J
F
P
1
1
6
7
B
J
F
P
1
1
6
8
 
B: 
%
 
V
i
a
b
i
l
i
t
y
0.8
0.6
0.4
0.2
0
1 CEM
ACH2
Jurkat
J1.1
U937
U1
OM10.1 DMSO CR8 MT-033 CR8#13 DMSO CR8 MT-033 CR8#13
50nM 10μM  
 
Figure 1.  Screening of CR8 derivatives on Tat-dependent transcription HIV-1 LTR.  A.  TZM-bl cells were transfected with 1ug of 
Tat and treated the next day with DMSO, or the indicated CR8 derivative compounds at 50nM.  48 hrs-post drug treatment, luciferase 
activity of the firefly luciferase was measured with the BrightGlo Luciferase Assay and luminescence was read from a 96 well plate 
on an EG&G Berthold luminometer.  Assays were performed in triplicate, average and standard deviations are shown. B. MTT assay 
of  CR8, MRT-033, and BJFP1154 (CR8#13) were tested on all infected ACH2, J1.1, OM10.1, U1 and uninfected CEM, Jurkat T-
cells, and U937 cells at 50nM and 10µM drug concentrations.391 
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Efficacy dependence of CR8#13 on microRNA 
machinery for transcription inhibition 
We previously observed that the parent, Cyc202, was an 
effective inhibitor against HIV-1 in T-cells but not in 
monocytes (Agbottah et al, 2005). Specifically, we 
observed that the integral microRNA machinery, Dicer 
and Drosha, were significantly decreased in monocytes 
leading us to hypothesize on the dependence of Cyc202 
on the microRNA machinery for efficacy (Klase et al, 
2007; Coley et al, Submitted). Since CR8#13 is derived 
from Cyc202, we looked at how the microRNA 
machinery, via the RITS or RISC complex would be 
involved in specifically inhibiting viral transcription. 
We proceeded to study the efficacy of the derived drugs 
in the presence or absence of Dicer, an integral part of 
cellular microRNA machinery. We implemented the use 
of the HCT116 colon carcinoma cell line that either 
contained a WT Dicer (HCT116 WT) or lacked the 
Dicer protein (HCT116 Dicer-/-).  These cells were first 
transfected with the HIV-1 LTR-CAT reporter 
construct. HIV-1 LTR transcription was activated with 
pc-Tat and treated at 6hrs with DMSO (negative 
control), Flavopiridol (positive control), CR8#13, 
F07#13, or 9AA (other inhibitors that are not ATP 
analogs). Cells were harvested 48hrs-post treatment and 
processed for CAT assays (Figure 2A and B). There 
was greater activation of the HIV-1 LTR in cells 
lacking detectable Dicer, resulting in significantly more 
viral transcription than in cells containing Dicer. This is 
consistent with the previous data indicating that Dicer 
plays an inhibitory role in HIV-1 transcription 
(Triboulet et al. 2007). 
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Figure 2.  Effect of Drugs on Tat-mediated transactivation in HCT116 WT and 
HCT116 Dicer-/- cells.  pHIV-1 LTR−CAT (1µg) construct was transfected in 
2×10
6 cells in the absence or presence of Tat (1µg). Six hours later, the 
transfected cells were treated with DMSO, Flavopirodol (100nM), CR8#13 
(100nM), F07#13 (100nM), and 9AA (1000nM). Treated cells were incubated 
in complete DMEM for 48hrs at 37°C. Cells were harvested and cell extracts 
were used for CAT analysis. One tenth the amount of HCT116 Dicer-/- extract 
compared to HCT116 WT was used for CAT analysis. Values represent the 
percentage of conversion of the [
14C] chloramphenicol substrate in the CAT 
assay.  Panel A shows results from HCT116 WT cells and panel B are from 
HCT116 Dicer-/- cells. C. Confirmation western blot for Dicer and PIWIL4 in 
the HCT116 WT and Dicer -/- cells. One hundred microgram of total extracts 
were ran on a 4-20% (w/v) SDS/PAGE and western blotted for  presence of 
Dicer, PIWIL4 and actin. D. CAT assay of Dicer WT HCT116 cells that had 
been treated with siRNA against Dicer,  transfection with Tat followed by drug 
treatment. 392 
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Flavopiridol and CR8#13 inhibited viral transcription 
significantly better in cells that contained Dicer (Figure 2A, 
Lanes 4 and 5).  F07#13 and 9AA, control drugs previously 
shown to inhibit viral transcription, had moderate effects 
(Figure 2A, Lanes 6-7).  It has previously been shown that 
9AA efficiently inhibited HIV-1 transcription (at higher 
concentrations) through the restoration of p53 and 
p21WAF1 functions (Guendel et al, 2009). F07#13 and 
9AA likely do not utilize the TAR microRNA pathway for 
their inhibitory activity in these cells.  Figure 2C 
substantiates that the presence of Dicer is significantly 
decreased in the HCT116 Dicer-/- cells. Importantly these 
cells contain miRNA which may be the product of PIWI 
expression. In order to provide further support that 
presence of Dicer has an effect on drug efficacy; a similar 
CAT assay was performed as in Figure 2A. siRNA against 
Dicer was transfected along with pther plasmids into 
HCT116 WT cells and CAT enzyme was detect in 2 days. 
When Dicer levels were decreased, the viral transcription 
inhibition caused by the drugs was also decreased (Figure 
2D). The dependence of CR8#13 and Flavopiridol on Dicer 
for increased transcription inhibition indicated that 
microRNA machinery may be important in increasing 
efficacy and specificity toward the HIV-1 promoter. 
We next examined whether these drugs were effective in 
cell lines infected with an HIV-1 construct. To this effect 
Jurkat T-cells and promonocytic U937 cells were 
transfected with pNL4.3 and then treated with 
Flavopiridol, CR8 and CR8#13. We previously showed 
that Dicer levels were low to undetectable in monocytes 
(Klase et al, 2007). Here, these promonocytic cells show 
undetectably low levels of Dicer, as compared with T-cells 
(Figure 3A). The presence of Dicer protein was detectable 
only when cells had differentiated into macrophages with 
PMA treatment. Once again, PIWIL4 levels are constantly 
present in these cells and could contribute to microRNA 
formation either at monocyte or macrophage stages. The 
supernatants from these cells were collected and processed 
for exogenous reverse transcriptase (RT) levels. From the 
results shown in Figure 3B, Flavopiridol was able to 
decrease RT levels in both cell lines. However both CR8 
and CR8#13 were effectively able to decrease RT levels in 
the Jurkat T-cell lines as compared to U937 monocytic 
cells. Along these lines, previous studies have shown that 
promonocytic cells expressed significantly less or non-
existent amounts of Dicer, as compared to T-cells (Klase 
et al, 2007). These results further suggest the dependence 
of CR8#13 effects on the microRNA machinery.  
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Figure 3.  RT assay to determine virus 
production in drug treated cells.  A.  
Western blot for Dicer, Drosha, Ago2 
and PIWIL4 in control T- cells (CEM) 
and monocytes (U937) are shown (50µg 
of total protein).  Dicer protein 
expression becomes apparent only after 
PMA treatment resulting in 
differentiation of cells into 
macrophages. PIWIL4 are present in 
both cell types. B. Jurkat T-cell and 
promonocytic U937 cells were 
electroporated with 5µg pNL4.3 
followed the next day by drug treatment 
of Flavopiridol (200nM), CR8 (100nM) 
or CR8#13 (50nM). Cell supernatants 
were collected at 48 hours post drug 
treatment. Viral supernatants (10µl) 
were incubated in a 96-well plate with 
reverse transcriptase (RT) reaction 
mixture overnight at 37°C, and 10µl of 
the reaction mix was spotted on a DEAE 
Filtermat paper, washed with 5% (w/v) 
Na2HPO4 followed by water wash, and 
then dried completely. RT activity was 
measured in a Betaplate counter. 393 
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CR8#13 does not affect cdk9 responsive cellular genes 
Flavopiridol at low concentrations is a known inhibitor of 
cdk9 (Chao et al, 2000); hence, we wished to determine if 
CR8#13 would have any effect on cdk9 responsive genes 
in vivo. Our ultimate goal has been to find an inhibitor that 
effects viral transcription at low IC50 with minimal 
inhibition on cellular genes necessary for normal cell 
development. We utilized a set of cellular and viral genes 
to test the effect of CR8#13 on their transcription using 
RT/PCR. Known cdk9 responsive cellular genes included: 
CIITA, IL-8, CAD, MCL-1, Cyclin D1, and PBX-1 
(Carlson et al, 1999; Kanazawa et al, 2000; Barboric et al, 
2001; Lam et al, 2001; Eberhardy and Farnham, 2002; 
Chao et al, 2003). Histone H2B gene served as a negative 
control for lack of cdk9 requirement for its gene 
expression (Medlin et al, 2005). Results in Figure 4 show 
that treatment of cells with CR8#13 at various 
concentrations (20, 50, 200nM) did not inhibit 
transcription of genes that were cdk9 responsive. This 
further reinforces the idea that the transcriptional 
inhibition caused by CR8#13 may be specific to HIV-1 
promoter and not cellular genes that utilize cdk9 pathway.   
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Figure 4.  Agarose gels showing a lack of effect on cellular 
genes controlled by cdk9 after treatment with CR8#13.  293T 
cells were treated with three different concentrations of CR8#13 
(20 nM, 50 nM, and 200 nM). Cells were processed 48hrs-post 
treatment for RT-PCR.  Effector cdk9 genes such as CIITA, IL-8, 
CAD, MCL-1, Cyclin D1, and PBX-1 were used in the RT-PCR. 
 
 
 
Possible effect of TAR microRNA in increasing the 
effectiveness of HIV-1 transcription inhibitors 
Latently infected cells produce a high level of short, 
abortive RNA transcripts only 50-100nt in length, that 
contain the HIV TAR stemloop (Adams et al, 1994). It has 
been shown that TAR serves as a substrate for Dicer 
resulting in short 21-22 RNA molecules capable of 
silencing HIV-1 transcription (Klase et al, 2007). Since 
these TAR-containing short transcripts are the dominant 
HIV-1 RNA produced in appreciable quantities during 
latency, it is possible that these RNA molecules could 
suppress viral gene expression. Our current studies point 
to cdk inhibitors functionally interacting with TAR 
microRNA, which affects RNA polymerase II processing, 
and may increase the efficacy of the drugs’ inhibition on 
the HIV-1 promoter. As seen in Figure 5A, a model for 
transcription argues that RNA polymerase II is 
phosphorylated at Ser5 at the initiation complex and Ser2 
on the elongating complex. RNA polymerase II associated 
with HIV-1 promoter is, however, phosphorylated on both 
Ser2 and 5 in the presence of Tat (Zhou et al, 2004). In 
order to ascertain whether or not cells treated with CDK 
inhibitor produce additional TAR derived miRNA, we 
utilized RNase protection assays to detect small RNA 
fragments corresponding to TAR sequence (Klase et al, 
2007). Briefly, a probe complementary to the entire length 
of the 5' portion of the TAR stem loop was designed, 
which would detect the generation of ~21nt RNAs from 
any position within that sequence. The results were 
considered positive if the 32nt probe was cleaved to ~21nt, 
indicating protection by a microRNA. The latently 
infected T-cell clone, ACH2, was treated with TNF (for 
viral induction) followed by treatment with Cyc202, CR8, 
and CR8#13. Thirty micrograms of total RNA from each 
condition was used for RPA analysis to detect the presence 
of the 5’ TAR miRNA. Higher levels of TAR and miTAR 
RNA were observed in CR8#13 treated cells as compared 
to Flavopiridol treatment (Figure 5B, Lanes 5 and 6).  This 
lead to further experimentation to determine levels of each 
of the microRNA produced from TAR region (3’TAR 
stem and 5’TAR stem) in presence of these drugs. 
 
Total RNA from the ACH2 cells treated with Flavopiridol, 
CR8, and CR8#13 were extracted and processed for RT-
PCR detection of microRNAs, specifically for the 3’TAR 
and 5’TAR stems regions. The QuantiMir RT Kit provides 
a simple and sensitive method to detect small RNA 
molecules. After total RNA is extracted, the microRNAs 
are polyA tagged and then an oligo-dT adaptor is 
annealed. At this point, RT is used to create first strand 
cDNAs. From here, standard end-point PCR can be used 
to detect specific microRNAs.  The product would be the 
adaptor (46bp) plus the miRNA (~2bp).  Results in Figure 
5C indicate that there is an increase in 3’TAR with each 
drug treatment over the untreated control  Flavopiridol and 
CR8#13 treatment exhibited a similar increase in 3’TAR 
microRNA levels.  In contrast, there was an increase in the 
5’TAR microRNA levels only with the cells treated with 
CR8#13. The results from Figure 5C could potentially 
explain the higher levels of miTAR observed in Figure 5B 
(Lane 5). As control we ran the RNA on an agarose gel to 
check for integrity of the total RNA (Figure 5D). Finally, 
we looked at the RT levels in the supernatant of these drug 
treated cells and found almost complete inhibition of virus 
replication in these cells (Figure 5E).  Collectively, these 
results lead us to hypothesize that the 5’TAR microRNA 
could potentially be responsible for the effective inhibitory 
effects of CR8#13.  Finally, this suggests that inhibitors of 
RNA polymerase II Ser2/Ser5 phosphorylation may slow 
down RNA polymerase II moving toward the 3’ end of the 
HIV-1 genome and create more short TAR transcripts than 
normally present in these cells, thus providing a 
mechanistic explanation of transcription inhibition 
observed with inhibitors, such as CR8#13.   394 
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Figure 5.  Increased production of TAR microRNA due to drug treatment.  A. Model of the effect of RNA polymerase  II 
phosphorylation on transcription. RNA polymerase  II CTD is hypo-phosphorylated at the initiation complex; Ser5 is only 
phosphorylated at the promoter clearance stage; and Ser2 is mostly phosphorylated at the elongation phase.  HIV-1 genome is unique in 
that it contains both Ser2 and Ser5 phosphorylation at the elongation stage (Zhou et al, 2004). Phosphorylation of Ser2 and Ser5 could be 
seen by multiple cyclin/cdk complexes. B. Ten micrograms of total RNA from TNF treated CEM (lane 1) and TNF treated ACH2 cells 
(lanes 2-6) were hybridized to a radiolabeled TAR 5’ probe and then treated with RNase A. Arrows indicate the probe protected by TAR 
at 27 nucleotides and the probe protected by a TAR miRNA at approximately 22nt. Cyc202 concentration at 500nM, CR8 at 100nM, 
CR8#13 at 50nM, and Flavopiridol at 50nM were used for these experiments. C. ACH2 cells were treated with Flavopiridol (50nM), 
CR8 (100nM) and CR8#13 (100nM). RNA was extracted 48hrs-post drug treatment.  500ng of RNA from the microRNA-enriched 
fraction was used to generate cDNA using the Quantimir kit (SBI).  RT reactions are performed followed by PCR in which a universal 
reverse primer is provided by the manufacturer.  Specific microRNA forward primers are identical in sequence to the microRNA of 
interest. PCR products corresponding to the amplified microRNAs were resolved in a 3.5% (w/v) agarose gel. The PCR products are at 
around 67bp as compared with the Fermentas 1kb DNA Plus Ladder. Increased amounts of 3’ and 5’ TAR microRNA were observed 
post drug treatment. D. Total RNA (1ug) from each samples was separated in a 1% (w/v) agarose gel. The location of both 18S and 28S 
are shown. E. RT assay was performed to detect viral levels in ACH2 cells after TNF and drug treatments. ACH2 cells were treated with 
Flavopiridol (50nM), Cyc202 (500nM), CR8 (100nM) and CR8#13(100nM). Supernatents were collected 48hrs later and used for RT 
assay. TNF treatment significantly increased RT levels in ACH2 cells and drug treatment was able to decrease RT levels. 
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TAR microRNA induce formation of repressive 
chromatin markers on the HIV-1 LTR 
Recent studies have suggested that TAR derived 
microRNA may have effects on chromatin structure (Klase 
et al, 2009). To test the ability of TAR derived microRNA 
to direct chromatin remodeling at the viral LTR, chromatin 
immunoprecipitation (ChIP) assays were performed to 
examine the recruitment of factors to the HIV-1 LTR.   
One such factor, HDAC-1, is a histone deacetylase shown 
to be involved in silencing of HIV-1 promoter (Easow et 
al, 2007). TZM-bl cells carrying integrated HIV-1 LTR 
were utilized for these experiments (Figure 6A).  In these 
cells LTR is already silenced.  Previous work in the field 
has shown that chronic treatment of HeLa cells with the 
HDAC inhibitor TSA abolishes the heterochromatic state 
(Cobb et al, 2005). We therefore treated the cells for seven 
days with a sub-lethal dose of the HDAC inhibitor TSA 
and assayed for factor occupancy on the promoter. 
Chromatin changes were verified by performing ChIP 
assays before and after TSA treatment using antibodies 
specific for inhibitory factors including the components of 
the RNAi machinery (Figure 6B). The rationale here was 
to see if silenced state (absence of TSA) would have 
differing factor occupancy as compared to active state 
(presence of TSA). The results in panel B established that 
the RNAi protein Argonaute and the histone modifiers 
Suv39H1 and SETDB1 are present at the latent LTR and 
are removed once they are treated with TSA. 
 
To evaluate the effect of TAR microRNA on recruitment 
of repressive chromatin remodeling factors to the HIV-1 
LTR, we TSA treated the TZM-bl cells for 7 days 
followed by removal of TSA and transfection of these 
cells with either TAR-WT or TAR-D RNA control. On 
day 7 TSA was removed and replaced with complete 
media, and on Day 8 cells were used for ChIP for presence 
of either HDAC-1 and/or Argonaute (Ago2) (Figure 6C). 
Results indicated that prior to TSA treatment, HDAC-1 
and Ago2 were associated with the LTR and this 
association was lost upon treatment with TSA (compare 
lanes 1 and 2). Transfection of the cells with TAR-WT 
RNA led to an increase in the reassociation of HDAC-1 
and Ago2 to the LTR after 24hrs as compared to the 
control RNA (compare lane 3 to 4). HDAC-1 and Ago2 
recruitment to an integrated LTR verifies that 
heterochromatin formation at the HIV-1 LTR is driven by 
RNAi mediated TAR microRNA.   
 
We wished to determine if Flavopiridol, CR8, and CR8#13 
treatments increased levels of TAR microRNA in the TSA-
treated and control TZM-bl cells. Total RNA was extracted 
from both sets of cells treated with Flavopiridol, CR8, and 
CR8#13 and processed for RT-PCR detection of 
microRNAs, specifically for the 3’TAR and 5’TAR 
molecules. The results from Figure 6D validate the presence 
of both 3’ and 5’ TAR microRNA in these cells. The TZM-
bl cells treated with TSA expressed higher amounts of both 
3’ and 5’ TAR microRNA when treated with Flavopiridol 
and CR8.  The addition of Flavopirodol, CR8, and 
especially CR8#13 significantly increased amount of the 3’ 
TAR microRNA in the non-TSA treated TZM-bl cells.  This 
was expected since previous results have shown that integral 
microRNA machinery (i.e., Ago2) can be found near the 
HIV-1 LTR before TSA treatment.  Finally, we observed a 
similar increase in the 3’ and 5’TAR microRNA from cells 
that had been treated first with TSA and then CR8#13. 
 
In order to observe the drug effects on heterochrmatin 
formation, a ChIP assay was performed on TZM-bl cells 
treated with TSA similar to Figure 6B and C, and then 
treated with CR8#13. The results from Figure 6E show 
that treatment with CR8#13 results in the re-recruitment 
of heterochromatin markers, such as HDAC1, Ago2, and 
Suv39H1 to the HIV-1 promoter. In addition to the ChIP 
assay, a Luciferase assay was performed on the TSA and 
CR8#13 treated cells. Results in Figure 6F show that 
TSA treatment resulted in increased Luciferase activity 
of the intergrated HIV-1-Luc in TZM-bl cells. Treatment 
with CR8#13 was able to decrease Luciferase activity in 
these cells.  Collectively, these results indicate that the 
HIV-1 TAR microRNA is responsible for the enhanced 
effectiveness of cdk inhibitors, especially CR8#13, on 
the HIV-1 promoter by recruiting both microRNA and 
chromatin remodeling complexes to the promoter 
proximal region. 
 
DISCUSSION 
 
A viral microRNA generated from full-length, doubly 
spliced or singly spliced HIV-1 transcripts could potentially 
inhibit viral replication, block translation of viral proteins or 
cause remodeling of the viral genome.  Since the integrated 
HIV-1 genome is associated with chromatin remodeling 
complexes and histone acetyl-transferases activity is 
involved with activation of the virus, it makes sense that a 
viral microRNA could have a significant role in the control 
of viral transcription. 
 
The TAR element, about 50 nucleotides long, at the 5’ end 
of the HIV-1 viral mRNA was one of the five structures 
within HIV that had a possibility of being processed by 
Dicer. The TAR element has been shown to be involved 
with activation of promoter proximal region and not so 
much elongation of transcription. It would be interesting if 
the TAR microRNA, rather than the entire hairpin, is 
actually the functioning sequence in regulating 
transcription. Further support of a role for TAR hairpins 
loaded into microRNA machinery is that TAR-RNA 
Binding Protein (TRBP) was identified as the human 
homologue of the Drosophila loquacious protein which is 
required for efficient loading of the microRNA into the 
RISC complex (Chendrimada et al, 2005). The fact that 
RNAi components, such as TRBP, can be found associated 
with the TAR element is strong evidence that TAR may be 
processed to yield microRNA. Previously, we successfully 
detected a TAR derived HIV-1 microRNA using RNase 
protection and subsequent pyrosequencing. We showed the 
presence of the 5’ and 3’ TAR microRNA in cell lines and 
de novo infection of primary cells and have cloned the TAR 
microRNAs from infected cells (Klase et al, 2009). The 
production of this TAR microRNA and binding to 
complementary genes could explain the downregulation of 
many cellular genes (Liang et al, 2005; Zhao et al, 2005). 
From various studies, latent cells have been shown to 
produce a high amount of short, abortive RNA transcripts 
only 50-100 nucleotides in length, that contain396 
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Figure 6.  HIV microRNAs specifically induce formation of repressive chromatin markers on the HIV-1 LTR. A. Model of TZM-bl 
cells suppression and activation. Trichostatin-A (TSA), a widely used HDAC inhibitor were used to activate the integrated HIV-1 LTR-
Luc transcription in TZM-bl and abolish the repressive heterochromatic state. Seven days post treatment of TSA, the TZM-bl were 
transfected with the TAR microRNA. B. ChIP assays were performed with the TSA treated TZM-bls. Primers specific for the HIV-1 
LTR were used to amplify DNA that was precipitated with each antibody. MicroRNA machinery (Ago2), histone methyltransferases 
(Suv39H1), chromatin remodeling markers (SETDB1, SETMAR), and transcription repressors (PIASγ) were downregulated after TSA 
treatment on the integrated HIV-LTR. C. ChIP assays were performed on several markers of chromatin repression (HDAC1) and 
microRNA machinery (Ago2) in TZMb1 cells. Primers specific for the HIV-1 LTR were used to amplify DNA that was precipitated 
with each antibody. Lane 1 shows basal levels of repressive markers on the HIV-1 LTR. Lane 2 shows that seven days of TSA treatment 
removes the markers of repressive chromatin. Lane 3 shows that the TAR-D mutant does not initiate a recruitment of repressive 
enzymes. Lane 4 demonstrates that addition of the WT-TAR molecule is sufficient to recruit Ago2 and HDAC1 back to the HIV-1 LTR 
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region. D. TZM-bl cells were treated with Flavopiridol (50nM), CR8 (100nM) and CR8#13 (100nM) after 7-day TSA treatment.  RNA 
was extracted 48hrs-post drug treatment.  500ng of RNA from the microRNA-enriched fraction was used to generate cDNA using the 
Quantimir kit (SBI) in order to poly-adenylate small RNA species. RT reactions were performed followed by PCR in which a universal 
reverse primer was provided by the manufacturer. Specific microRNA forward primers are identical in sequence to the microRNA of 
interest. PCR products corresponding to the amplified microRNAs were separated in a 3.5% (w/v) agarose gel. The PCR products are at 
around 67bp as compared with the Fermentas 1kb DNA Plus Ladder.  Increased levels of 3’TAR microRNA were produced post 
CR8#13 treatment. E. ChIP assays were performed on several markers of chromatin repression (HDAC1, Suv39H1) and microRNA 
machinery (Ago2) in TZMb1 cells. Primers specific for the HIV-1 LTR were used to amplify DNA that was precipitated with each 
antibody. Lane 1 indicates basal levels of repressive markers on the HIV-1 LTR. Lane 2 indicates that seven days of TSA treatment 
removes the markers of repressive chromatin and Lane 3 shows results that the CR8#13 treatment is sufficient to recruit HDAC1, Ago2 
and Suv39H1 back to the HIV-1 LTR region. F. Luciferase assays were performed on the cells used in Figure 6E. Luciferase activity 
increased with TSA treatment and then decreased post-CR8#13 treatment. 
 
 
 
the HIV-1 TAR hairpin (Adams et al, 1994). Of the entire 
HIV-1 genome, these TAR-containing short transcripts are 
the only HIV RNA produced in large quantities during 
latency. Therefore, it is possible that the microRNAs 
generated from TAR may act to suppress viral gene 
expression and alter host-cell proteins levels in order to 
maintain the latent state. 
 
While current anti-retroviral drugs can halt viral 
replication, latent HIV-1 infections persist in infected 
patients. Any halt or interruption to the therapy quickly 
results in a resurgence of viral titers due to the reservoir of 
latent infections. Consequently, research into the 
mechanisms underlying viral latency has taken on 
increasing significance and few labs have developed 
numerous models of latent infections.  Understanding how 
latently infected cells function, enable virus replication, 
and avoid immune response is the key to finding an 
effective treatment for HIV-1 infection. 
 
Since HIV-1 TAR microRNA plays significant roles in 
manipulating both cellular and viral mechanisms, it is no 
surprise that this viral microRNA could also be involved 
with drug efficacy. As previously reported, cdk/cyclin 
complexes play an important role in viral replication. 
Effective cdk inhibitors could play a significant role in 
suppressing viral replication and possibly better therapeutics 
for HIV-1 infection. As previously shown, Cyc202 (R-
Roscovitine), was able to prevent cdk2/cyclin E binding to 
the HIV-1 LTR and inhibit HIV-1 in T-cells, monocytes, 
and peripheral blood mononuclear cells at a low IC50 
(Agbottah et al, 2005). These results also showed that 
Cyc202 was able to inhibit HIV-1 more effectively in T-
cells as compared to monocytes at equivalent drug 
concentrations. When using co-crystal structures, the purine 
ring of Cyc202 and of CR8, a derivative of Cyc202, is 
sandwiched between the side chain of Ile10 and of Leu134 
of cdk2. Compared to the Cyc202 phenyl group, the phenyl 
ring of CR8 is positioned further away from Phe82 side 
chain. The CR8 isomers were roughly 25 times more potent 
than Cyc202.  Through our initial drug screens, CR8 was 
able to effectively eliminate HIV-1 infected cells better than 
the uninfected cells. 
 
We then attempted to find a derivative of CR8 that could 
potentially eliminate HIV-1 transcription completely without 
affecting essential cellular genes that incorporate the use of 
certain cdks. The most promising was CR8#13, which 
decreased viral transcription significantly more than the other 
roscovitine derivatives. Not only did CR8#13 downregulate 
viral transcription, it also did not affect cell viability or 
downstream cdk9 effector genes. This suggests that CR8#13 
is capable of specifically targeting HIV-1 transcripts. 
 
To understand the mechanism behind this cdk inhibitor, 
we attempted to examine possible reasons why this class 
of drugs is effective against HIV-1 transcription. The 
combined observations that the parental Cyc202 was more 
effective in T-cells rather than monocytes (Agbottah et al, 
2005), and that monocytes expressed significantly less 
Dicer (Klase et al, 2007) led us to predict that microRNA 
was involved in drug efficacy. In fact, both Flavopiridol 
and the CR8#13 exhibited a dependence on the presence 
of the viral TAR microRNA. These two drugs exhibited 
significantly more downregulation of viral transcription 
compared to other drugs when Dicer is present. The 
difference between Flavopiridol and CR8#13 is also 
highlighted by the forms of microRNA that are produced 
following treatment. When looking specifically at the TAR 
microRNA produced from drug treated infected cells, the 
CR8#13 caused production of more viral microRNA than 
Flavopiridol. In addition, CR8#13 caused a significant 
increase in both the 3’TAR and 5’TAR, while Flavopiridol 
only increased the 3’TAR microRNA. The drugs that are 
more effective in the presence of Dicer utilize microRNAs 
to downregulate viral transcription; however, Flavopiridol 
and CR8#13 seems to utilize different microRNA 
mechanisms to inhibit HIV-1.   
 
To understand mechanistically how the TAR microRNA is 
inhibiting HIV-1 transcription, we incorporated the use of 
TZM-bl cells.  Using the TZM-bl cells, we are able to 
show that chromatin remodeling complexes and 
microRNA machinery are not bound to the HIV-1 LTR 
when the LTR becomes activated.  However, when the 
TAR microRNA is reapplied, these complexes are re-
linked to the LTR to terminate RNA polymerase II 
transcription and more TAR microRNA is created.  Once 
again, CR8#13 was able to induce the production of both 
the 3’ and 5’TAR microRNA, due to this premature 
termination of RNA polymerase II and recruitment of 
microRNA machinery to the HIV-1 LTR.  Overall, a cdk 
inhibitor at low concentrations could potentially inhibit 
Pol II phosphorylation and elongation, increase TAR 
microRNA levels and therefore result in a higher 
specificity of inhibition toward the HIV-1 promoter as 
compared to other cellular or viral promoters.  Along these 
lines Figure 7 shows such a model and further points to398 
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Figure 7.  Model for cdk inhibitor-mediated viral microRNA production and transcriptional inhibition. During viral transcription, 
Tat/pTEF-b complexes increase phosphorylation of RNA polymerase II, leading to increased transcriptional elongation. In contrast, 
cdk inhibitors reduce phosphorylation of RNA polymerase II (at either Ser 2, 5 or both), consequently decreasing elongation. As a 
result, increased TAR transcripts are produced which aid in the recruitment of RNA interference machinery and heterochromatin 
remodeling complexes to the HIV-1 promoter, inhibiting transcription. This form of inhibition may ultimately lead to DNA 
methylation as a permanent epigenetic mark on HIV-1 LTR.  
 
where an increase in TAR levels leads to the recruitment 
of RNAi machinery and heterochromatin remodeling 
complexes to the HIV-1 promoter.  
 
In conclusion, the HIV-1 field has progressed rapidly in 
developing an effective therapy, HAART, to prevent 
infection from spreading to other healthy cell. However, 
new treatments need to be developed in order to destroy 
latently infected cells and eliminate infection. It appears 
that the production of viral TAR microRNA, allows 
HIV-1 to both suppress apoptotic cellular mechanisms 
and also keep viral genome activation at a minimum until 
these latently infected cells are stimulated to produce 
more virus and potentially infect other healthy cells.   
These microRNA pathways also enable certain drugs to 
have greater efficacy and can play vital roles in drug 
functional pathways. Understanding latency and how 
microRNA mechanisms contribute is integral to finding a 
therapeutic to effectively treat HIV-1 infection. 
 
CONCLUSIONS 
 
 We have demonstrated that CR8#13, a third generation 
cdk inhibitor, is an effective inhibitor of HIV-1 LTR at 
the viral promoter. 
 
 We showed that CR8#13 requires the cellular 
microRNA machinery to achieve significant 
transcriptional inhibition of HIV-1. 
 CR8#13 exerts its inhibitory effect only on HIV-1 LTR 
expression, as we demonstrated that normal cellular 
gene expression is unaffected following drug 
treatment. 
 
 We provide a mechanistic explanation for CR8#13 
based HIV-1 inhibition by showing that CR8#13 
increases 3’ and 5’ TAR microRNA production in 
HIV-1 infected cells. 
 
 We demonstrated that the increased TAR microRNA in 
infected cells causes formation of repressive chromatin 
structures on the HIV-1 promoter, thus inducing viral 
transcriptional inhibition. 
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HAART: Highly Active Antiretroviral Therapy 
LTR: Long Terminal Repeat 
TAR: Transactivation Response Element 
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CDK: Cyclin-dependent Kinase 
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ChIP: Chromatin Immunoprecipitation 
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